Abstract
Pituitary adenylate cyclase-activating polypeptide (PACAP) is a pleiotropic and multifunctional neuropeptide having neurotrophic, neuroprotective, and general cytoprotective actions in a variety of tissues based on its anti-apoptotic, anti-inflammatory, and antioxidant effects. Several studies have demonstrated its cardioprotective effects in vitro and in various animal models. However, few data are available on the presence of PACAP in human cardiac tissues and its role in the pathomechanism and progression of different cardiac disorders, particularly heart failure. Earlier, our research group has shown PAC1 receptor immunoreactivity in human heart tissue samples and we have found significantly elevated PACAP27- and PACAP38-like immunoreactivity in ischemic cardiac samples compared to valvular abnormalities with radioimmunoassay. In the last few years, numerous studies examined the presence and the changes of PACAP levels in different human tissue samples and biological fluids to show alterations in different physiological and pathological conditions. Therefore, the aim of the present study was to measure the alterations of blood PACAP levels in chronic heart failure caused by primary dilated cardiomyopathy or ischemic cardiomyopathy and to examine the possible relationship between serum levels of PACAP, N-terminal prohormone of brain natriuretic peptide (NT-proBNP), and systolic left ventricular function, the most reliable biomarkers of heart failure. In the group of mild heart failure patients, a significant strong negative correlation was detected. Furthermore, in moderate heart failure, we found a significant moderate negative correlation between PACAP and NT-proBNP levels only in ischemic subgroup. Positive correlation was found between serum PACAP level and ejection fraction only in patients with heart failure due to ischemic cardiomyopathy but not in patients with primary dilated cardiomyopathy. In summary, remarkable differences were observed between the ischemic and non-ischemic heart failure suggesting that PACAP might play an important role in the pathomechanism and progression of ischemic heart failure and it might be a potential biomarker of cardiac diseases in the future.
Similar content being viewed by others
References
Alston EN, Parrish DC, Hasan W, Tharp K, Pahlmeyer L, Habecker BA (2011) Cardiac ischemia-reperfusion regulates sympathetic neuropeptide expression through gp130-dependent and independent mechanisms. Neuropeptides 45(1):33–42. https://doi.org/10.1016/j.npep.2010.10.002
Anversa P, Sonnenblick EH (1990) Ischemic cardiomyopathy: pathophysiologic mechanisms. Prog Cardiovasc Dis 33(1):49–70. https://doi.org/10.1016/0033-0620(90)900039-5
Arimura A, Somogyvari-Vigh A, Miyata A, Mizuno K, Coy DH, Kitada C (1991) Tissue distribution of PACAP as determined by RIA: highly abundant in the rat brain and testes. Endocrinology 129(5):2787–2789. https://doi.org/10.1210/endo.129-5-2787
Baranowska-Bik A, Kochanowski J, Uchman D, Wolinska-Witort E, Kalisz M, Martynska L, Baranowska B, Bik W (2013) Vasoactive intestinal peptide (VIP) and pituitary adenylate cyclase activating polypeptide (PACAP) in humans with multiple sclerosis. J Neuroimmunol 263(1–2):159–161. https://doi.org/10.1016/j.jneuroim.2013.08.012
Baron A, Monnier D, Roatti A, Baertschi AJ (2001) Pituitary adenylate cyclase-activating polypeptide activates K(ATP) current in rat atrial myocytes. Am J Physiol Heart Circ Physiol 280(3):H1058–H1065. https://doi.org/10.1152/ajpheart.2001.280.3.H1058
Borzsei R, Mark L, Tamas A, Bagoly T, Bay C, Csanaky K, Banki E, Kiss P, Vaczy A, Horvath G, Nemeth J, Szauer E, Helyes Z, Reglodi D (2009) Presence of pituitary adenylate cyclase activating polypeptide-38 in human plasma and milk. Eur J Endocrinol 160(4):561–565. https://doi.org/10.1530/EJE-08-0911
Bukovics P, Czeiter E, Amrein K, Kovacs N, Pal J, Tamas A, Bagoly T, Helyes Z, Buki A, Reglodi D (2014) Changes of PACAP level in cerebrospinal fluid and plasma of patients with severe traumatic brain injury. Peptides 60:18–22. https://doi.org/10.1016/j.peptides.2014.07.001
Calupca MA, Vizzard MA, Parsons RL (2000) Origin of pituitary adenylate cyclase-activating polypeptide (PACAP)-immunoreactive fibers innervating guinea pig parasympathetic cardiac ganglia. J Comp Neurol 423(1):26–39. https://doi.org/10.1002/1096-9861(20000717)423:1<26::AID-CNE3>3.0.CO;2-C
Caobelli F, Bengel FM (2015) Ischaemic vs non-ischaemic dilated cardiomyopathy: the value of nuclear cardiology techniques. J Nucl Cardiol 22(5):971–974. https://doi.org/10.1007/s12350-015-0128-1
Chang Y, Lawson LJ, Hancock JC, Hoover DB (2005) Pituitary adenylate cyclase-activating polypeptide: localization and differential influence on isolated hearts from rats and guinea pigs. Regul Pept 129(1-3):139–146. https://doi.org/10.1016/j.regpep.2005.02.012
Clason TA, Girard BM, May V, Parsons RL (2016) Activation of MEK/ERK signaling by PACAP in guinea pig cardiac neurons. J Mol Neurosci 59(2):309–316. https://doi.org/10.1007/s12031-016-0766-z
De Leon H, Boue S, Szostak J, Peitsch MC, Hoeng J (2015) Systems biology research into cardiovascular disease: contributions of lipidomics-based approaches to biomarker discovery. Curr Drug Discov Technol 12(3):129–154. https://doi.org/10.2174/1570163812666150702123319
DeHaven WI, Cuevas J (2002) Heterogeneity of pituitary adenylate cyclase-activating polypeptide and vasoactive intestinal polypeptide receptors in rat intrinsic cardiac neurons. Neurosci Lett 328(1):45–49. https://doi.org/10.1016/S0304-3940(02)00445-7
Dornberger V, Dittrich HD, Busch R (2015) Echocardiographic evaluation of systolic left ventricular function in heart failure: value of alternative parameters for determination of ejection fraction. Herz 40(2):185–193. https://doi.org/10.1007/s00059-015-4205-7
Duffy JY, Hameed AB (2015) Cardiovascular disease screening. Semin Perinatol 39(4):264–267. https://doi.org/10.1053/j.semperi.2015.05.004
Elefsiniotis IS, Ketikoglou I, Kafiri G, Pantazis KD, Moulakakis A, Mavrogiannis C (2003) Plasma pituitary adenylate cyclase activating polypeptide (PACAP) levels in chronic hepatitis B patients under lamivudine treatment. Eur J Gastroenterol Hepatol 15(11):1209–1216. https://doi.org/10.1097/01.meg.0000085489.12407.bd
Eneman B, Freson K, van den Heuvel L, van Hoyweghen E, Collard L, Vande Walle J, van Geet C, Levtchenko E (2015) Pituitary adenylate cyclase-activating polypeptide deficiency associated with increased platelet count and aggregability in nephrotic syndrome. J Thromb Haemost 13(5):755–767. https://doi.org/10.1111/jth.12891
ESC Guideline for the diagnosis and treatment of acute and chronic heart failure (2016) Heart Journal
Farnham MM, Inglott MA, Pilowsky PM (2011) Intrathecal PACAP-38 causes increases in sympathetic nerve activity and heart rate but not blood pressure in the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 300(1):H214–H222. https://doi.org/10.1152/ajpheart.00662.2010
Gasz B, Racz B, Roth E, Borsiczky B, Ferencz A, Tamas A, Cserepes B, Lubics A, Gallyas F Jr, Toth G, Lengvari I, Reglodi D (2006a) Pituitary adenylate cyclase activating polypeptide protects cardiomyocytes against oxidative stress-induced apoptosis. Peptides 27(1):87–94. https://doi.org/10.1016/j.peptides.2005.06.022
Gasz B, Racz B, Roth E, Borsiczky B, Tamas A, Boronkai A, Gallyas F Jr, Toth G, Reglodi D (2006b) PACAP inhibits oxidative stress-induced activation of MAP kinase-dependent apoptotic pathway in cultured cardiomyocytes. Ann N Y Acad Sci 1070(1):293–297. https://doi.org/10.1196/annals.1317.029
Gopal DM, Sam F (2013) New and emerging biomarkers in left ventricular systolic dysfunction—insight into dilated cardiomyopathy. J Cardiovasc Transl Res 6(4):516–527. https://doi.org/10.1007/s12265-013-9462-3
Han P, Liang W, Baxter LC, Yin J, Tang Z, Beach TG, Caselli RJ, Reiman EM, Shi J (2014a) Pituitary adenylate cyclase activating polypeptide is reduced in Alzheimer disease. Neurology 82(19):1724–1728. https://doi.org/10.1212/WNL.0000000000000417
Han P, Tang Z, Yin J, Maalouf M, Beach TG, Reiman EM, Shi J (2014b) Pituitary adenylate cyclaseactivating polypeptide protects against β-amyloid toxicity. Neurobiol Aging 35(9):2064–2071. https://doi.org/10.1016/j.neurobiolaging.2014.03.022
Hoover DB, Girard BM, Hoover JL, Parsons RL (2013) PAC1 receptors mediate positive chronotropic responses to PACAP-27 and VIP in isolated mouse atria. Eur J Pharmacol 713(1–3):25–30. https://doi.org/10.1016/j.ejphar.2013.04.037
Jakab B, Reglodi D, Jozsa R, Hollosy T, Tamas A, Lubics A, Lengvari I, Oroszi G, Szilvassy Z, Szolcsanyi J, Nemeth J (2004) Distribution of PACAP-38 in the central nervous system of various species determined by a novel radioimmunoassay. J Biochem Biophys Methods 61(1–2):189–198. https://doi.org/10.1016/j.jbbm.2004.03.002
Jiang L, Wang WH, Dong XQ, Yu WH, Du Q, Yang DB, Wang H, Shen YF (2016) The change of plasma pituitary adenylate cyclase-activating polypeptide levels after aneurysmal subarachnoid hemorrhage. Acta Neurol Scand 197(1-2):35–42. https://doi.org/10.1016/j.jbbm.2004.03.002
Kanasaki H, Purwana IN, Oride A, Mijiddorj T, Sukhbaatar U, Miyazaki K (2013) Circulating kisspeptin and pituitary adenylate cyclase-activating polypeptide (PACAP) do not correlate with gonadotropin serum levels. Gynecol Endocrinol 29(6):583–587. https://doi.org/10.3109/09513590.2013.788624
Kelder JC, Cramer MJ, Verweij WM, Grobbee DE, Hoes AW (2011a) Clinical utility of three B-type natriuretic peptide assays for the initial diagnostic assessment of new slow-onset heart failure. J Card Fail 17(9):729–734. https://doi.org/10.1016/j.cardfail.2011.04.013
Kelder JC, Cowie MR, McDonagh TA, Hardman SM, Grobbee DE, Cost B, Hoes AW (2011b) Quantifying the added value of BNP in suspected heart failure in general practice: an individual patient data meta-analysis. Heart 97(12):959–963. https://doi.org/10.1136/hrt.2010.220426
Lamouche S, Yamaguchi N (2003) PACAP release from the canine adrenal gland in vivo: its functional role in severe hypotension. Am J Physiol Regul Integr Comp Physiol 284(2):R588–R597. https://doi.org/10.1152/ajpregu.00466.2002
Lenti L, Domoki F, Kis D, Hegyi O, Toth GK, Busija DW, Bari F (2007) Pituitary adenylate cyclase-activating polypeptide induces pial arteriolar vasodilation through cyclooxygenase-dependent and independent mechanisms in newborn pigs. Brain Res 1165:81–88. https://doi.org/10.1016/j.brainres.2007.06.032
Lopez JP, Diallo A, Cruceanu C, Fiori LM, Laboissiere S, Guillet I, Fontaine J, Ragoussis J, Benes V, Turecki G, Ernst C (2015) Biomarker discovery: quantification of microRNAs and other small non-coding RNAs using next generation sequencing. BMC Med Genet 8(1):35. https://doi.org/10.1186/s12920-015-0109-x
Ma BQ, Zhang M, Ba L (2015) Plasma pituitary adenylate cyclase-activating polypeptide concentrations and mortality after acute spontaneous basal ganglia hemorrhage. Clin Chim Acta 439:102–106. https://doi.org/10.1016/j.cca.2014.10.010
Maron BJ, Towbin JA, Thiene G, Antzelevitch C, Corrado D, Arnett D, Moss AJ, Seidman CE, Young JB (2006) American Heart Association, Council on Clinical Cardiology, Heart Failure and Transplantation Committee, Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups, Council on Epidemyology and Prevention. Contemporary definitions and classification of the cardiomyopathies: an American Heart Association Scientific Statement from the Council on Clinical Cardiology, Heart Failure and Transplantation Committee; Quality of Care and Outcomes Research and Functional Genomics and Translational Biology Interdisciplinary Working Groups; and Council on Epidemiology and Prevention. Circulation. 113(14):1807–1816. doi: https://doi.org/10.1161/CIRCULATIONAHA.106.174287
McMurray JJ, Adamopoulos S, Anker SD, Auricchio A, Bohm M, Dickstein K, Falk V, Filippatos G, Fonseca C, Gomez-Sanchez MA, Jaarsma T, Køber L, Lip GY, Maggioni AP, Parkhomenko A et al (2012) ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012: the Task Force for the Diagnosis and Treatment of Acute and Chronic Heart Failure 2012 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association (HFA) of the ESC. Eur Heart J 33(14):1787–1847. https://doi.org/10.1093/eurheartj/ehs104
Merriam LA, Roman CW, Baran CN, Girard BM, May V, Parsons RL (2012) Pretreatment with nonselective cationic channel inhibitors blunts the PACAP-induced increase in guinea pig cardiac neuron excitability. J Mol Neurosci 48(3):721–729. https://doi.org/10.1007/s12031-012-9763-z
Miyata A, Arimura A, Dahl RR, Minamino N, Uehara A, Jiang L, Culler MD, Coy DH (1989) Isolation of a novel 38 residue-hypothalamic polypeptide which stimulates adenylate cyclase in pituitary cells. Biochem Biophys Res Commun 164(1):567–574. https://doi.org/10.1016/0006-291X(89)91757-9
Mori H, Nakamachi T, Ohtaki H, Yofu S, Sato A, Endo K, Iso Y, Suzuki H, Takeyama Y, Shintani N, Hashimoto H, Baba A, Shioda S (2010) Cardioprotective effect of endogenous pituitary adenylate cyclase-activating polypeptide on doxorubicin-induced cardiomyopathy in mice. Circ J 74(6):1183–1190. https://doi.org/10.1253/circj.CJ-09-1024
Otto C, Hein L, Brede M, Jahns R, Engelhardt S, Grone HJ, Schutz G (2004) Pulmonary hypertension and right heart failure in pituitary adenylate cyclase-activating polypeptide type I receptor-deficient mice. Circulation 110(20):3245–3251. https://doi.org/10.1161/01.CIR.0000147235.53360.59
Racz B, Gasz B, Borsiczky B, Gallyas F Jr, Tamas A, Jozsa R, Lubics A, Kiss P, Roth E, Ferencz A, Toth G, Hegyi O, Wittmann I, Lengvari I, Somogyvari-Vigh A, Reglodi D (2007) Protective effects of pituitary adenylate cyclase activating polypeptide in endothelial cells against oxidative stress-induced apoptosis. Gen Comp Endocrinol 153(1–3):115–123. https://doi.org/10.1016/j.ygcen.2006.12.006
Racz B, Reglodi D, Horvath G, Szigeti A, Balatonyi B, Roth E, Weber G, Alotti N, Toth G, Gasz B (2010) Protective effect of PACAP against doxorubicin-induced cell death in cardiomyocyte culture. J Mol Neurosci 42(3):419–427. https://doi.org/10.1007/s12031-010-9349-6
Reglodi D, Tamas A (2016) Pituitary adenylate cyclase activating polypeptide — PACAP. Springer, Switzerland. https://doi.org/10.1007/978-3-319-35135-3
Reglodi D, Gyarmati J, Ertl T, Borzsei R, Bodis J, Tamas A, Kiss P, Csanaky K, Banki E, Bay C, Nemeth J, Helyes Z (2010) Alterations of pituitary adenylate cyclase-activating polypeptide-like immunoreactivity in the human plasma during pregnancy and after birth. J Endocrinol Investig 33(7):443–445. https://doi.org/10.1007/BF03346621
Reglodi D, Helyes Z, Nemeth J, Vass R, Tamas A (2016) PACAP as a potential biomarker—alterations of PACAP levels in human physiological and pathological conditions. In: Reglodi D, Tamas A (eds) Pituitary adenylate cyclase activating polypeptide — PACAP. Springer, Switzerland, pp 815–832. https://doi.org/10.1007/978-3-319-35135-3_48
Ressler KJ, Mercer KB, Bradley B, Jovanovic T, Mahan A, Kerley K, Norrholm SD, Kilaru V, Smith AK, Myers AJ, Ramirez M, Engel A, Hammack SE, Toufexis D, Braas KM, Binder EM, May V (2011) Post-traumatic stress disorder is associated with PACAP and the PAC1 receptor. Nature 470(7335):492–497. https://doi.org/10.1038/nature09856
Richardson RJ, Grkovic I, Anderson CR (2003) Immunohistochemical analysis of intracardiac ganglia of the rat heart. Cell Tissue Res 314(3):337–350. https://doi.org/10.1007/s00441-003-0805-2
Roth E, Weber G, Kiss P, Horvath G, Toth G, Gasz B, Ferencz A, Gallyas F Jr, Reglodi D, Racz B (2009) Effects of PACAP and preconditioning against ischemia/reperfusion-induced cardiomyocyte apoptosis in vitro. Ann N Y Acad Sci 1163(1):512–516. https://doi.org/10.1111/j.1749-6632.2008.03635.x
Sano H, Miyata A, Horio T, Nishikimi T, Matsuo H, Kangawa K (2002) The effect of pituitary adenylate cyclase activating polypeptide on cultured rat cardiocytes as a cardioprotective factor. Regul Pept 109(1–3):107–113. https://doi.org/10.1016/S0167-0115(02)00193-3
Santaguida PL, Don-Wauchope AC, Oremus M, McKelvie R, Ali U, Hill SA, Booth RA, Brown JA, Bustamam A, Sohel N, Raina P (2014) BNP and NT-proBNP as prognostic markers in persons with acute decompensated heart failure: a systematic review. Heart Fail Rev 19(4):453–470. https://doi.org/10.1007/s10741-014-9442-y
Schoenfeld LK, Souder JA, Hardwick JC (2000) Pituitary adenylate cyclase-activating polypeptide innervation of the mudpuppy cardiac ganglion. Brain Res 882(1-2):180–190. https://doi.org/10.1016/S0006-8993(00)02885-7
Subramaniam V, Chuang G, Xia H, Burn B, Bradley J, Maderdrut JL, Coy DH, Varner KJ (2017) Pituitary adenylate cyclase-activating polypeptide (PACAP) protects against mitoxantrone-induced cardiac injury in mice. Peptides 95:25–32. https://doi.org/10.1016/j.peptides.2017.07.007
Szanto Z, Sarszegi Z, Reglodi D, Nemeth J, Szabadfi K, Kiss P, Varga A, Banki E, Csanaky K, Gaszner B, Pinter O, Szalai Z, Tamas A (2012) PACAP immunoreactivity in human malignant tumor samples and cardiac diseases. J Mol Neurosci 48(3):667–673. https://doi.org/10.1007/s12031-012-9815-4
Tuka B, Helyes Z, Markovics A, Bagoly T, Szolcsanyi J, Szabo N, Toth E, Kincses ZT, Vecsei L, Tajti J (2013) Alterations in PACAP-38-like immunoreactivity in the plasma during ictal and interictal periods of migraine patients. Cephalalgia 33(13):1085–1095. https://doi.org/10.1177/0333102413483931
Ushiyama M, Sugawara H, Inoue K, Kangawa K, Yamada K, Miyata A (2006) Characterization of the PAC1 variants expressed in the mouse heart. Ann N Y Acad Sci 1070(1):586–590. https://doi.org/10.1196/annals.1317.086
Vamos Z, Ivic I, Cseplo P, Toth G, Tamas A, Reglodi D, Koller A (2014) Pituitary adenylate cyclase-activating polypeptide (PACAP) induces relaxations of peripheral and cerebral arteries, which are differentially impaired by aging. J Mol Neurosci 54(3):535–542. https://doi.org/10.1007/s12031-014-0349-9
Vaudry D, Falluel-Morel A, Bourgault S, Basille M, Burel D, Wurtz O, Fournier A, Chow BK, Hashimoto H, Galas L, Vaudry H (2009) Pituitary adenylate cyclase-activating polypeptide and its receptors: 20 years after the discovery. Pharmacol Rev 61(3):283–357. https://doi.org/10.1124/pr.109.001370
Wei Y, Mojsov S (1996) Multiple human receptors for pituitary adenylyl cyclase-activating polypeptide and vasoactive intestinal peptide are expressed in a tissue-specific manner. Ann N Y Acad Sci 805:624–627
Yamamoto K, Burnett JC, Bermudez EA, Jougasaki M, Bailey KR, Redfield MM (2000) Clinical criteria and biochemical markers for the detection of systolic dysfunction. J Card Fail 6(3):194–200. https://doi.org/10.1057/jcaf.2000.9676
Acknowledgments
The authors thank all the volunteers.
Funding
This work was supported by the following grants: National Research Development and Innovation Fund K119759, GINOP-2.3.2-15-2016-00050 “Pepsys,” EFOP-3.6.1.-16-2016-00004, EFOP-3.6.2-16-2017-00009, EFOP-3.6.2-16-2017-00008, TAMOP 4.2.4.A/2-11-1-2012-0001 National Excellence Program, UNKP-16-4-IV New National Excellence Program of the Ministry of Human Capacities, MTA TKI 14016 Program, and Bolyai Scholarship. The present scientific contribution is dedicated to the 650th anniversary of the foundation of the University of Pecs, Hungary.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of Interest
The authors declare that they have no conflict of interest.
Rights and permissions
About this article
Cite this article
Sarszegi, Z., Szabo, D., Gaszner, B. et al. Examination of Pituitary Adenylate Cyclase-Activating Polypeptide (PACAP) as a Potential Biomarker in Heart Failure Patients. J Mol Neurosci 68, 368–376 (2019). https://doi.org/10.1007/s12031-017-1025-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s12031-017-1025-7